250+ investors that invest in your industry and stage
Get 250+ investors tailored to your startup
  • Invest in your industry and stage
  • Emails & contact info included
  • Excel and CSV export
  • Automatically
Trusted by 3,000+ startups

Top 50 Biotechnology VC (Venture Capital) Funds in Sweden in July 2025

A list of 50 VC (Venture Capital) funds that invest in Biotechnology startups based in Sweden. We rank investors based on the number of investments they made in Biotechnology companies from Sweden. We update this investor list every month.

Top 50 Biotechnology VC (Venture Capital) Funds in Sweden in July 2025

Investor Biotechnology Sweden investments
Sciety 16
Chalmers Ventures AB 15
Industrifonden 11
Almi Invest 11
Navigare Ventures 6
HealthCap 5
Karolinska 5
SEB Venture Capital 4
Novo Holdings 4
Norrsken VC 4
Inventure 3
Voima Ventures 3
Crowberry Capital 3
BackingMinds 3
Partnerinvest Norr 3
Nina Capital 2
Länsförsäkringar 2
I Love Lund 2
LIU Invest 2
LU Holding 2
Segulah Medical Acceleration 2
Boehringer Ingelheim Venture Fund 2
EIR Ventures 2
Faro Capital 2
Noaber 2
Hadean Ventures 2
Johnson & Johnson Innovation 1
Karolinska Institutet Holding 1
Ysios Capital 1
TPG Growth 1
CBC Investment Group 1
Idinvest Partners 1
Northislet 1
European Investment Bank 1
Falkenbergs Sparbanks Foundation 1
FBG Invest 1
GOBIA Enterprises 1
Porte Monnaie 1
Kurma Partners 1
Investinor 1
LifeArc Ventures 1
RV Invest 1
Nordic Science Investments 1
Klimatet Invest 1
Bertebos Foundation 1
Additio Investment Group 1
Fåhraeus Startup and Growth 1
Hans and Barbara Bergström 1
Teknoinvest 1
Plantbase Foundation 1
Find investors that fund startups like yours. Automatically.
Our algorithm will find investors that invest in your industry, stage, and geography.
Investor list
Sciety VC Fund · Stockholm, Stockholms Lan, Sweden · 2 investments in the past 12 months
Whether you are an investor or entrepreneur, partner with Sciety to achieve impactful returns and elevate your life science business in the Nordics.
Show more
Investment focus
  • Health Care, Biotechnology, Pharmaceutical
  • Seed, Series A, Funding Round
  • Sweden, Ukraine
Portfolio highlights
  • Capitainer — Capitainer enables patients to collect their own volume-defined dried blood spot at home.Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitaineroffers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually.
  • PeptiSystems — PeptiSystems offers a new generation of instruments for solid-phase synthesis production of peptide and oligonucleotide therapeutics. Our instruments are used for process development and large-scale GMP and non-GMP manufacturing based on flowthrough column technology.
  • TIRmed Pharma — TIRmed Pharma develops drug candidates addressing major clinical needs.
Chalmers Ventures AB VC Fund · Göteborg, Vastra Gotaland, Sweden · 10 investments in the past 12 months
We are a leading tech investor & venture builder in the Nordics. Taking deep tech from lab to market.WELCOMEINVESTMENTS
Show more
Investment focus
  • Software, Biotechnology, Information Technology
  • Pre-Seed, Seed, Funding Round
  • Sweden
Portfolio highlights
  • Embedl AB — Efficient Deep Learning by Deep Learning model optimization
  • Adsorbi — Adsorbi use cellulose from the Nordic forest to help air purification companies to capture gaseous air pollutants.
  • Swedish Algae Factory — Our algae materials replace harmful and less efficient chemicals in high-end organic personal care products and has the potential of increasing the efficiency of solar panels.
Industrifonden VC Fund · Stockholm, Stockholms Lan, Sweden · 7 investments in the past 12 months
Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.
Show more
Investment focus
  • Software, Biotechnology, Information Technology
  • Funding Round, Series A, Seed
  • Sweden, United States, Denmark
Portfolio highlights
  • Fibbl — Fibbl is the world's first cost-effective end-to-end solution for 3D and AR focused visual marketing. Integrate 3D & AR into e-commerce and marketing in minutes.Fibbl have industrialized the process of producing photorealistic 3D models for consumer products from global brands. Fibbl has the world's largest 3D model database forconsumer products.Learn more - https://www.fibbl.com/
  • Gårdsfisk — Gårdsfisk is a company managing fishing farms. Gårdsfisks develops a new method for fish farming on land. The cultivation takes place in large pools in a closed system, where the nutrient residual water can be reused as fertilizer on the fields.
  • Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
Almi Invest VC Fund · Stockholm, Stockholms Lan, Sweden · 8 investments in the past 12 months
Almi Invest is Sweden’s most active early-stage venture capital firm, investing in scalable startups across Sustainability, Industry, Tech, and Life Science.We invest from pre-seed to Series A, always co-investing with independent private investors to accelerate innovation and long-term success. Our portfolio spans sustainable solutions,industrial innovation, deep tech, SaaS, and life science, supporting startups that drive economic and environmental progress.With €430 million under management and over 1,000 investments since 2009, we have backed leading companies like MIPS, Tobii, and Neo4j, with notable exits to Google, Apple, Microsoft, and Qlik.Beyond capital, we offer engaged ownership, providing strategic guidance, active board participation, and access to an extensive investor network.Almi Invest is part of the Almi Group and is funded by the European Regional Development Fund, Almi AB, and regional partners.
Show more
Investment focus
  • Software, Health Care, Information Technology
  • Funding Round, Seed, Pre-Seed
  • Sweden, United States, United Kingdom
Portfolio highlights
  • Embedl AB — Efficient Deep Learning by Deep Learning model optimization
  • Epigenica — Epigenica focuses on advancing epigenomics through its EpiFinder™ platform, a multiplexed ChIP-seq technology for high-throughput analysis of epigenetic marks. The company offers R&D services for the development of therapeutic molecules and diagnostic methods using epigenetics. Epigenica aims to improve scientists' ability to capture andextract insights from the epigenome, contributing to precision medicine and the discovery of new biomarkers.
  • Polar Light Technologies — Polar Light Technologies focuses on developing the next generation of Nano and micro LED technology.
Navigare Ventures VC Fund · Stockholm, Stockholms Lan, Sweden · 2 investments in the past 12 months
Welcome to Navigare Ventures. We invest in transformational early-stage companies at the frontier of science and technology.
Show more
Investment focus
  • Biotechnology, Health Care, Energy
  • Seed, Funding Round, Pre-Seed
  • Sweden, Denmark
Portfolio highlights
  • Arevo — Arevo offers liquid and granular amino acid fertilizer technologies for faster and better plant establishment.
  • Repli5 — Enabling autonomous vehicles with synthetic data. We automate the creation of synthetic data and digital twins.
  • Epigenica — Epigenica focuses on advancing epigenomics through its EpiFinder™ platform, a multiplexed ChIP-seq technology for high-throughput analysis of epigenetic marks. The company offers R&D services for the development of therapeutic molecules and diagnostic methods using epigenetics. Epigenica aims to improve scientists' ability to capture andextract insights from the epigenome, contributing to precision medicine and the discovery of new biomarkers.
HealthCap VC Fund · Stockholm, Stockholms Lan, Sweden · 5 investments in the past 12 months
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series A, Funding Round
  • United States, Sweden, France
Portfolio highlights
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • HelloBetter — HelloBetter (hellobetter.de) was founded in 2015 under the name GET.ON Institut für Online Gesundheitstrainings GmbH (geton-institut.de) by internationally renowned research psychologists, and in close partnership with one of the largest public health care insurance companies in Germany (BARMER). HelloBetter is a pioneer in the field of e-mentalhealth and a leading provider of online mental health courses. Its work has a strong scientific basis – the courses were developed, evaluated, and implemented in a practice setting, and their effectiveness has been proven in 33 randomized controlled trials according to the highest standards of scientific practice. HelloBetter offers the widest range of evidence-based online mental health courses worldwide, with 11 digital courses covering 8 problem areas (stress, depression, insomnia, depression in the case of chronic illness, chronic pain, alcohol consumption, excessive worry, and panic and anxiety).In October 2021, the digital therapeutic 'HelloBetter Stress and Burnout' has been permanently approved by the German Federal Institute for Drugs and Medical Devices (BfArM) as a Digital Health Application (DiGA) and thus is available by prescription free of charge for more than 50 million adults. It is the world’s first and so far only prescription digital therapeutic for the treatment of burnout symptoms.Through diverse cooperations with national and international research groups (including FAU Erlangen, University of Ulm, VU Amsterdam, and Harvard University) HelloBetter finds practical applications for the latest research innovations. Our products and our team have been awarded numerous national and international prizes. These include the Novartis & Sandoz/Hexal Digital Health Prize 2018, the Comenius Award of the European Federation of Psychologists’ Association, and the Good Practice in Mental Health & Wellbeing seal of approval as part of the EU Compass 2018, which recognises high-quality mental health initiatives in Europe in order to guide health care providers to effective and proven services.
  • Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
Karolinska VC Fund · Solna, Stockholms Lan, Sweden
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Funding Round, Seed, Series A
  • Sweden, Denmark, United States
Portfolio highlights
  • PharmNovo — Latest News from PharmNovo. Learn more about pain, neuropathic pain, chronic pain. Treatment with our lead candidate PN6047. Therapy market, our networks. There is a huge unmet medical need for people suffering from chronic pain.
  • OssDsign AB — Giving patients back the life they deserve, Catalyst nanosynthetic bone graft, orthobiologics
  • Modus Therapeutics — Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.
SEB Venture Capital VC Fund · Stockholm, Stockholms Lan, Sweden
SEB Venture Capital is a Fintech investor that helps entrepreneurs and innovators launch and grow profitable businesses. They primarily serve as a strategic corporate venture focused on Fintech investments, with the option of partnering with SEB. They are also on the hunt for game-changing inventive solutions to new technologies that will make thefinancial industry smarter, safer, and more environmentally responsible, as well as more user-friendly. They also function as an evergreen fund, giving them the flexibility and staying strength to focus on long-term wealth development depending on what is best for the firm and its shareholders.
Show more
Investment focus
  • Software, Information Technology, Financial Services
  • Funding Round, Series A, Series B
  • Sweden, Denmark, United Kingdom
Portfolio highlights
  • EnginZyme — EnginZyme is a biotechnology company that specializes in biocatalysis. It creates products for easy and cost-efficient implementation of biocatalytic processes and helps the chemical industry transition to a sustainable way of operating.The company is driven by a mission to make biocatalysis the first choice for chemical process designersworldwide.
  • Qvantum — Qvantum is driven by a passion for a sustainable future and we are changing the way the cities of Europe are heated.
  • CorPower Ocean — CorPower Ocean is a turnkey supplier of wave energy systems, enabling customers to generate clean electricity from ocean waves - bringing stability to the renewable energy mix.
Novo Holdings VC Fund · Hellerup, Hovedstaden, Denmark · 21 investments in the past 12 months
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • United States, Denmark, United Kingdom
Portfolio highlights
  • Supira Medical — Next Generation Solution for Temporary Mechanical Circulatory Support Developing a low-profile, high-flow percutaneous ventricular assist device (pVAD) for high risk coronary intervention and cardiogenic shock. Clinical Need Percutaneous ventricular assist devices (pVADs) are placed to provide temporary mechanical support, assisting the native pumping action of
  • Sparrow Quantum — Sparrow Quantum, a global leader in quantum photonic chip technology. Explore innovative solutions driving advancements in quantum computing, communication, and beyond. Stay ahead with cutting-edge technologies shaping the future.
  • Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
Norrsken VC VC Fund · Stockholm, Stockholms Lan, Sweden · 12 investments in the past 12 months
We are a venture capital fund investigating in Start-Ups solving the worlds biggest problems while building massive businesses.
Show more
Investment focus
  • Software, Food and Beverage, Health Care
  • Seed, Series A, Funding Round
  • Sweden, Germany, United Kingdom
Portfolio highlights
  • Kapu — We are an online shopping community that helps you save even more on your everyday essentials when you buy together with your friends.
  • trawa — The partner for renewable and affordable electricity for businesses. Get electricity directly from solar and windparks with corporate PPAs.
  • Beans — Beans is on a mission to help the planet by reducing food waste, saving products, and offering them through an online grocery platform at discounted prices.
Inventure VC Fund · Helsinki, Southern Finland, Finland · 4 investments in the past 12 months
Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more.
Show more
Investment focus
  • Software, Information Technology, Health Care
  • Seed, Series A, Series B
  • Finland, Sweden, Denmark
Portfolio highlights
  • Hedera Dx — A diagnostics platform that makes liquid biopsies a reality in cancer care
  • Moncyte Health — Unique technology and novel data for personalized and optimal treatment of high cholesterol
  • Avenue Biosciences — From biotechnology tools to therapy discovery and development: Our platform enhances production yield and the quality of your end product.
Voima Ventures VC Fund · Helsinki, Southern Finland, Finland · 11 investments in the past 12 months
Voima Ventures’ mission is to solve major global problems by combining science, entrepreneurship, and value adding capital. They shed light on the ideas and technology which require time and courage to build. Industry domains include bio and new materials, medical technologies and life sciences, imaging and optics, IoT and electronics, robotics,software & ICT and AI. In addition, Voima Ventures has invested in more than 30 deep tech startups, including companies like Solar Foods, Infinited Fiber Company, and Dispelix. Cornerstone investors are VTT Technical Research Centre of Finland and European Investment Fund (EIF), backed by Finnish private and institutional investors.
Show more
Investment focus
  • Biotechnology, Health Care, Medical Device
  • Seed, Pre-Seed, Funding Round
  • Finland, Sweden, Norway
Portfolio highlights
  • Hormona — Understand your hormones with the Hormona app. Monitor hormone levels, track symptoms, forecast cycles, and access personalized wellness tips for a balanced life.
  • Epigenica — Epigenica focuses on advancing epigenomics through its EpiFinder™ platform, a multiplexed ChIP-seq technology for high-throughput analysis of epigenetic marks. The company offers R&D services for the development of therapeutic molecules and diagnostic methods using epigenetics. Epigenica aims to improve scientists' ability to capture andextract insights from the epigenome, contributing to precision medicine and the discovery of new biomarkers.
  • Alba Health — Discover your baby's gut health & microbiome for the best start in life.
Crowberry Capital VC Fund · Reykjavík, Gullbringusysla, Iceland · 4 investments in the past 12 months
Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first.
Show more
Investment focus
  • Software, Gaming, Health Care
  • Seed, Series A, Pre-Seed
  • Iceland, Denmark, Finland
Portfolio highlights
  • Tiimo — Tiimo helps you manage your daily life and improve your wellbeing. Visualize your day. Improve your routines. Stress less.
  • Quanscient — We are building next generation simulation software-as-a-service utilizing Quantum computing algorithms. Our specialty domain of simulations is Computational Electromagnetics.
  • Porcelain Fortress — Porcelain Fortress was founded by a small band of romantics in the summer of 2016 in Reykjavik, Iceland.
BackingMinds VC Fund · Stockholm, Stockholms Lan, Sweden · 4 investments in the past 12 months
We help great minds unleash their full potential!
Show more
Investment focus
  • Medical Device, SaaS, Information Technology
  • Seed, Funding Round, Pre-Seed
  • Sweden, Denmark, Finland
Portfolio highlights
  • NitroVolt — NitroVolt: the next generational step of sustainable ammonia.
  • Serviceform — Welcome to future of communication - the truly all-in-one conversion and management software built for established businesses. Start now!
  • Techarena — Since 2014 Techarena is the platform for innovation and Tech in the Nordics. From supporting startups and scaleups to bringing the Tech and Business world together at Scandinavia's Biggest Events.
Partnerinvest Norr VC Fund · Piteå, Norrbottens Lan, Sweden · 2 investments in the past 12 months
Partnerinvest Norr is a private equity firm specialized in software, security, and biometrics sectors. Partnerinvest Övre Norrland AB is a venture capital firms that seeks to invest in limited companies which have are in the expansion phase.
Show more
Investment focus
  • Software, Information Technology, Manufacturing
  • Seed, Funding Round, Series A
  • Sweden, United States
Portfolio highlights
  • Elastisys — Succeed with your cloud native journey as an organization developing and operating software critical to our society. NIS2, ISO-27001, GDPR.
  • Senseworks — Senseworks is an insight platform that enables colleagues to collaborate effectively with customers by providing a single source of truth for accounting data.
  • Cold River Games — Cold River Games is a Swedish game studio currently developing the ARPG Crystalfall.
Nina Capital VC Fund · Barcelona, Catalonia, Spain · 8 investments in the past 12 months
We deploy early stage capital to fuel the growth of need-driven health technology companies.
Show more
Investment focus
  • Health Care, Artificial Intelligence, Medical
  • Seed, Pre-Seed, Series A
  • United States, United Kingdom, Germany
Portfolio highlights
  • CryoCloud — CryoCloud Accelerate your protein structure determination - Bring your cryo-EM data analysis to the next level by using our cloud-based image analysis workflow.
  • Sonar — Sonar is a scalable mental health platform for schools. We use a combination of AI and human connection to ensure every student is seen and supported. For educators, Sonar offers actionable insights to improve mental wellbeing, empower your staff, and boost student outcomes.
  • MedaSystems — Streamline patient and provider inquiries for Expanded Access or Compassionate Use with secure, 21st Century Cures Act compliant, cloud software.
Länsförsäkringar VC Fund · Stockholm, Stockholms Lan, Sweden · 3 investments in the past 12 months
Länsförsäkringar is a Swedish group of public insurance companies.
Show more
Investment focus
  • Real Estate, Manufacturing, Apps
  • Seed, Funding Round, Post-IPO Equity
  • Sweden
Portfolio highlights
  • Stendorren Fastigheter — Stendorren Fastigheter is a company involved in the real estate industry. It develops, owns, operates, and maintains industrial, logistical, and warehouse facilities. The business offers adequate and suitable space on fair lease terms through its tenant.
  • Phenaros Pharmaceuticals — Data-centric drug discovery with AI, Phenomics and Automation.
  • Swedish Logistic Property — Swedish Logistic Property (SLP) specializes in the development and management of logistics properties across Sweden. With a focus on energy efficiency, SLP provides modern logistics solutions tailored to meet the needs of various businesses. The company's portfolio includes strategically located properties designed to support efficientlogistics and supply chain operations. SLP also engages in the acquisition and development of new properties, aiming to expand its footprint in the logistics real estate market. The company's commitment to sustainability is evident in its construction practices and the operation of its logistics facilities.
I Love Lund VC Fund · Lund, Skane Lan, Sweden
I Love Lund is a venture capital firm.The firm seeks opportunities to invest in pre-seed rounds
Show more
Investment focus
  • Analytics, Biotechnology, Market Research
  • Seed, Pre-Seed, Funding Round
  • Sweden
Portfolio highlights
  • Bionamic — Bionamic provides solutions for the analysis of life science data to reduce or eliminate the manual steps between raw data and results.
  • Parlametric — Parlametric is a research-based company that specializes in analytics, business intelligence, and market research services.
  • Trackpaw Scientific — Contributing to the development of safe and effective pharmaceuticals at increased speed and quality by digitalising the preclinical study landscape.
LIU Invest VC Fund · Linköping, Ostergotlands Lan, Sweden
LIU invests in companies that are based on projects and ideas from Linköping University. LIU Invest is focused on investments in early phases. Investments are typically 250 000, but can be doubled by an additional investment.
Show more
Investment focus
  • Biotechnology, Information Technology, Health Care
  • Funding Round, Seed, Pre-Seed
  • Sweden
Portfolio highlights
  • Cellfion — Cellfion provides sustainable materials for next level clean energy storage and conversion devices.​
  • LunaMicro — Technology company developing textile pumps based on electroosmosis and conducting polymers for a wide variety of applications including outdoor clothing, PPE, and medicine.
  • Polar Light Technologies — Polar Light Technologies focuses on developing the next generation of Nano and micro LED technology.
LU Holding VC Fund
LU Holding is a Lund University’s investment company.
Show more
Investment focus
  • Biotechnology
  • Pre-Seed
  • Sweden
Portfolio highlights
  • Bionamic — Bionamic provides solutions for the analysis of life science data to reduce or eliminate the manual steps between raw data and results.
  • Trackpaw Scientific — Contributing to the development of safe and effective pharmaceuticals at increased speed and quality by digitalising the preclinical study landscape.
Segulah Medical Acceleration VC Fund · Stockholm, Stockholms Lan, Sweden
Segulah Medical Acceleration is a Scandinavia-based investment company focusing on innovative medical technology companies in Europe.
Show more
Investment focus
  • Health Care, Medical Device, Biotechnology
  • Series A, Series D, Series B
  • Sweden, Germany, United States
Portfolio highlights
  • Protembis — ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation.
  • Navinci Diagnostics — Navinci is a Swedish biotech company specializing in innovative in situ proximity ligation assay-based solutions for spatial proteomics.
  • Signifier Medical Technologies — Driving Innovation in the Sleep Market Signifier Medical Technologies (SMT) is a medical technology company focused on the development and commercialisation of innovative and non-invasive solutions for patients with sleep-disordered breathing conditions and snoring. Pioneers in challenging the wisdom of conventional sleep apnoea and snoring treatments, we've created the first daytime therapy that tackles the root cause of sleep-disordered breathing by physiologically retraining the airway against collapse.
Boehringer Ingelheim Venture Fund VC Fund · Ingelheim Am Rhein, Rheinland-Pfalz, Germany · 3 investments in the past 12 months
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Seed
  • United States, Germany, Belgium
Portfolio highlights
  • Nuevocor — Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts.
  • Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
  • Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
EIR Ventures VC Fund · Stockholm, Stockholms Lan, Sweden
EIR Ventures is a new Life Science Venture Group in the Nordics.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Seed, Funding Round
  • Denmark, Sweden, United States
Portfolio highlights
  • Henlez — Henlez is a Danish startup company.
  • ArgusEye — ArgusEye - Innovative Sensor Solutions - Real-time monitoring and control of biological systems and processes - Patented sensor technology
  • Moleculent — Moleculent is adding a functional layer of biology to pave the way for unparalleled advancements in biological research.
Faro Capital VC Fund · Buenos Aires, Distrito Federal, Argentina
FARO is an Argentina company over 10 years of experience in the development and operation of integrated projects in the agribusiness sector. All projects FARO own position it as a reference and leader both locally and internationally.Among his various projects, FARO operates the largest tree planting pecan nut Latin America, with projection tobecome the largest southern hemisphere and one of the largest in the world. This project is structured under different vehicles, including Alto Pecan stands, the first real estate development of nautical fields planted with pecan nut Latin America, located in Villa Paranacito, Entre Ríos . Another project is AgroConsortium, productive trust for the production and marketing of cereals and oilseeds in leased farms located in different productive areas in Argentina and potentially in the region. Finally, thanks to the expertise acquired in agribusiness, FARO developed his own business model for productive land conversion. Its aim is to position rural properties whose productive potential is not reflected in the price and complement the cycle with the economic use of land in intensive production, short and medium term.Since 2006, the Investor Group is a strategic partner OMBU FARO for all investment portfolios development ventures related to agribusiness, that focus on supply both local and international markets.
Show more
Investment focus
  • Biotechnology, Gaming, Medical
  • Series A, Seed, Funding Round
  • Sweden, United States
Portfolio highlights
  • Bionamic — Bionamic provides solutions for the analysis of life science data to reduce or eliminate the manual steps between raw data and results.
  • Bluwhale — Unlock Web3 Wallet Potential with AI Insights. Supercharge Your Business Growth
  • IntuiCell — IntuiCell develops a fundamentally new recursive computing architecture and associated technology platform.
Noaber VC Fund · Lunteren, Gelderland, The Netherlands
Noaber Ventures invests in initiatives that bring social transformations using information technology.
Show more
Investment focus
  • Health Care, Medical, Fitness
  • Seed, Series A, Funding Round
  • The Netherlands, Israel, Sweden
Portfolio highlights
  • Newsenselab (M-sense) — M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
  • Elsa — Elsa is a platform for patient driven research for better drugs, health and prevention. Elsa lets patients become their own personal researchers by providing them with a better understanding around how lifestyle factors may affect their disease activity measurements for chronic disease. To support them from a scientific perspective, Elsa gives themaccess to data on their specific disease (initially we work with rheumatoid arthritis) through the Riskminder foundation and scientific studies at Karolinska Institutet.
  • Alba Health — Discover your baby's gut health & microbiome for the best start in life.
Hadean Ventures VC Fund · Oslo, Oslo, Norway
Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series A, Funding Round, Series B
  • Sweden, Norway, Austria
Portfolio highlights
  • SciRhom — SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development.
  • Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
  • Alex Therapeutics — The Alex DTx Platform enables partners within pharma and health care to effectively and reliably launch new DTx treatments by leveraging existing insights, modules, processes and data.
Johnson & Johnson Innovation VC Fund · Cambridge, Massachusetts, United States · 15 investments in the past 12 months
JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson Innovation. Learn more about our equity investment strategy.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • United States, Israel, France
Portfolio highlights
  • Stylus Medicine — Stylus Medicine, Inc. is a biotechnology company dedicated to developing transformative in vivo genetic medicines.
  • PAQ Therapeutics — PAQ Therapeutics is developing KRAS degraders for deadly cancers without good treatment options.
  • Prazer Therapeutics — Prazer Therapeutics assists patients suffering from intractable diseases through the use of logical and innovative drug design approaches. They willaccomplished this through the use of new and innovative drug development platforms, such as rational molecular drug design technology and next-generation protein degradation technology.
Karolinska Institutet Holding VC Fund · Stockholm, Stockholms Lan, Sweden
Karolinska Institutet Holding is a subsidiary of KI Holding AB.
Show more
Investment focus
  • Biopharma, Biotechnology, Pharmaceutical
  • Seed
  • Sweden
Portfolio highlights
  • AAX Biotech — AAX Biotech specializes in next-generation antibody therapeutics through our two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. OurTechnologies: Seqitope™ is a high-resolution, high throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics.Opti-mAb™ is a new scFv format with dramatically improved expression levels and reduced aggregation tendencies. This will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies.
Ysios Capital VC Fund · San Sebastian, Pais Vasco, Spain · 4 investments in the past 12 months
Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • Spain, United States, Switzerland
Portfolio highlights
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • Memo Therapeutics — Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer
  • Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
TPG Growth VC Fund · San Francisco, California, United States · 3 investments in the past 12 months
TPG Growth was founded in 2007 to specialize in growth equity and middle-market buyout opportunities. Taking a long-term and hands-on approach to partnership, we identify unique companies across the U.S., Europe, Africa, and Asia and help them achieve their full potential. We can assist at all stages of a company’s growth, from its inception to itsinternational expansion, by drawing on our geography-specific experience and expert global operational resources from the TPG platforms. TPG Growth manages more than $7 billion in assets across a variety of sectors including media, technology, and industrials.
Show more
Investment focus
  • Health Care, Software, Biotechnology
  • Series C, Series B, Private Equity
  • United States, India, China
Portfolio highlights
  • Fibe — Get instant loans up to Rs. 5L with tenures up to 24 months & rates as low as 2.5% p.m. Check your eligibility now.
  • Homrich Berg — Homrich Berg is a personal wealth management firm based in Atlanta, GA helping families protect, grow, and manage their wealth since 1989.
  • SK Finance — Easy and fastest Car Loan, Tractor Loan, Secured Business Loan, Business Loan, Bike Loan from best finance company operating in Gujarat, Rajasthan, Punjab, Haryana, Maharashtra, Chhattisgarh, Madhya Pradesh and Uttarakhand.
CBC Investment Group VC Fund · Gothenburg, Vastra Gotaland, Sweden
CBC Investment Group started in 2009 in the midst of the financial crisis. The banks were on their knees, start-ups of small and medium-sized companies - all of a sudden they saw their credit and credit promises turned into demands for quick repayment and empty words. Serious talented entrepreneurs' ideas and companies risked going completelyunnecessary. In response to this crisis, they started the CBC Investment Group.
Show more
Investment focus
  • Biotechnology, Software, SaaS
  • Funding Round, Seed, Series B
  • Sweden, Denmark, Germany
Portfolio highlights
  • GLX Analytix — GLX Analytix is ​​a biomedical company that develops a new technology to identify a biomarker. The company was founded in 2019 and is based in Copenhagen, Denmark.
  • Swiftly — World's first AI that applies for jobs. Say goodbye to creating CV's, searching and applying for jobs. Let Swiftly do it for you! Welcome to the new age.
  • Hugel Control — HUGEL, Inc. strives to be a global company that continuously creates innovative products, promotes universal health, and improves the quality of life through state-of-the-art technology and creativity.
Idinvest Partners VC Fund · Paris, Ile-de-France, France
Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.
Show more
Investment focus
  • Biotechnology, Software, Health Care
  • Series B, Series A, Funding Round
  • France, United States, Spain
Portfolio highlights
  • Corti — Corti offers a digital assistant, augmenting medics in improving patient outcomes and internal performance.
  • Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
  • BreezoMeter — BreezoMeter offers personalized air quality & pollen data as well as active fire alerts with worldwide coverage & accuracy down to the street level.
Northislet VC Fund
North islet Tech & Life Science Investments Learn More
Show more
Investment focus
  • Biotechnology
  • Funding Round
  • Sweden
Portfolio highlights
  • BioLamina — BioLamina offers laminin cell culture matrix, the only laminins that are the original, full length, human recombinant laminins on the market.
  • AAX Biotech — AAX Biotech specializes in next-generation antibody therapeutics through our two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. OurTechnologies: Seqitope™ is a high-resolution, high throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics.Opti-mAb™ is a new scFv format with dramatically improved expression levels and reduced aggregation tendencies. This will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies.
European Investment Bank VC Fund · Luxembourg, Luxembourg, Luxembourg · 25 investments in the past 12 months
The European Investment Bank (EIB) offers lending, borrowing, and treasury services primarily within the European Union. It provides project loans for public and private sectors, loans to banks and intermediaries, structured finance products, guarantees, and securitization instruments for debts. Additionally, EIB offers equity and fund investmentproducts, including infrastructure and environmental funds, as well as venture capital funds. EIB also supports microfinance and risk-sharing finance for research and innovation and provides technical expertise for sustainable energy projects. Its services include infrastructure advisory, urban development support, guarantees for transport infrastructure, and funding for public-private partnerships and small- to medium-sized enterprises. The bank serves various sectors, including transportation, energy, health, education, and agriculture.
Show more
Investment focus
  • Biotechnology, Health Care, Energy
  • Debt Financing, Post-IPO Debt, Funding Round
  • Germany, France, The Netherlands
Portfolio highlights
  • Amadix — Amadix develops and commercializes breakthrough discoveries in cancer diagnosis with a clear commercial rationale, addressing unmet medical needs in oncology. After analytical validation and demonstration of clinical validity and utility through international multicentre studies, the products will be commercialized worldwide.The most advancedproduct developed by Amadix is Colofast, an innovative non-invasive screening signature for colorectal cancer (CRC) and advanced adenoma diagnosis in blood designed to solve a significant health priority: the high mortality rate due to colon cancer worldwide (around half of the diagnosed patients).Amadix team consist of industry veterans with robust expertise in the Oncology Diagnostic area. They are a top level management team with international experience in cancer diagnostics, the pharmaceutical industry, the biotechnology sector and intellectual property. Amadix also has independent board members with international profiles and many years of experience in oncology and diagnostics, who advise the management team on strategy, commercialization and business development in Europe and the US.
  • Greenlight Biosciences — Next Generation Crop Protection
  • Azienda Comprensoriale Acquedottistica — ACA Spa is an integrated water service company.
Falkenbergs Sparbanks Foundation VC Fund
Falkenbergs Sparbanks Foundation
Show more
Investment focus
  • Biotechnology, Manufacturing, Food Processing
  • Funding Round
  • Sweden
Portfolio highlights
  • Mycorena — Fungi-based, next-generation vegan protein. A food manufacturing solution superior to plants, using significantly less resources.
FBG Invest VC Fund
FBG Invest
Show more
Investment focus
  • Biotechnology, Manufacturing, Food Processing
  • Funding Round
  • Sweden
Portfolio highlights
  • Mycorena — Fungi-based, next-generation vegan protein. A food manufacturing solution superior to plants, using significantly less resources.
GOBIA Enterprises VC Fund · Gothenburg, Vastra Gotaland, Sweden
GOBIA Enterprises is owned by Jan G Smith who has been active in the pharmaceutical industry.
Show more
Investment focus
  • Eyewear, Health Care, Health Diagnostics
  • Seed
  • Sweden
Portfolio highlights
  • Profundus Imaging — Profundus' retinal imaging technology enables researchers and clinicians in particular to visualise subclinical changes of retinal disease.
  • Thioredoxin Systems — Thioredoxin Systems AB is developing an innovative antibiotic regimen for complicated urinary tract infections caused by antibiotic-resistant bacteria. The
Porte Monnaie VC Fund
Porte Monnaie is an early and active investor for startup companies and passive investors in listed companies with growth potential. Porte-Monnaie's mission is to invest in Swedish companies.
Show more
Investment focus
  • Health Care, Biotechnology
  • Seed
  • Sweden
Portfolio highlights
  • Gedea Biotech — Gedea Biotech develops an antibiotic-free, safe and effective treatment of vaginal fungal infections. Vaginal yeast infections are a major problem that affects about 75% of all women at some point in life. Gedea Biotech's substance, GA101, is a natural substance that has always been part of their environment. It acts by lowering the pH as wellas providing a physical barrier protection and inhibiting biofilm formation. The first product will be a topical treatment of vaginal fungal infections.
Kurma Partners VC Fund · Paris, Ile-de-France, France · 8 investments in the past 12 months
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more
Investment focus
  • Health Care, Biotechnology, Pharmaceutical
  • Series A, Series B, Seed
  • France, Spain, Switzerland
Portfolio highlights
  • Poppins — Mila merges music, technology, and neuroscience to reshape therapy into a musical experience. We create musical games for children based on neurologic music therapy methods. These games are designed to address learning dissabilities like dyslexia, providing a digital treatment at home and helping identify these conditions. Behind these games, weleverage data science and new technologies to interpret learning, language, and motor performance into a cognitive score. Our goal is to improve the process for patients receiving treatment and to reaching the vast undiagnosed majority.
  • Shorla Pharma — Shorla Pharma is an Irish specialty pharmaceutical company. It is growing portfolio brings accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical impact.
  • Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
Investinor VC Fund · Trondheim, Sor-Trondelag, Norway
Investinor invests in Norwegian based, high potential companies that are internationally oriented and in the phases ranging from early growth to expansion. The company has BNOK 4.2 ($500 m) under management and focus on companies within the internet, software, semiconductors, energy, cleantech, marine and life sciences sectors.
Show more
Investment focus
  • Software, Biotechnology, Manufacturing
  • Funding Round, Seed, Series A
  • Norway, United States, Switzerland
Portfolio highlights
  • Calluna Pharma — Join Calluna Pharma to transform therapeutics for inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, we can revolutionize patient care.
  • Ignite — A powerful & easy spend management tool to accelerate your procurement success by bringing clarity, clean data & sophisticated analytics to your fingertips
  • Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
LifeArc Ventures VC Fund · London, England, United Kingdom · 5 investments in the past 12 months
LifeArc Ventures a self-funding medical research charity that invests in Seed and Series-A stage Biotech and Healthtech companies.
Show more
Investment focus
  • Health Care, Fitness, Wellness
  • Series A, Seed
  • United Kingdom, United States
Portfolio highlights
  • GlycoEra — GlycoEra is a CustomGlycan platform that unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics.
  • Maxion Therapeutics — Maxion Therapeutics helps in learning transformative therapies. It uses this technology to deliver long-acting, safe, and effective medications against previously inaccessible targets.
  • Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
RV Invest VC Fund · Ravensburg, Baden-Wurttemberg, Germany · 3 investments in the past 12 months
RV Invest early and stand alongside founders and researchers to bring outstanding ideas to the market.
Show more
Investment focus
  • Health Care, Therapeutics, Biotechnology
  • Series A
  • United States
Portfolio highlights
  • Akribion Genomics — Specific, versatile, effective RNA-guided cell depletion
  • Arda Therapeutics — Arda Therapeutics is a biotechnology company taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions. Their approach starts by using single-cell data to identify pathogenic cells and specific markers to target them. They then design therapies to eliminate these - and only these - cells.Arda wasfounded in 2021 in the San Francisco Bay Area, CA.
  • Alesta Therapeutics — Alesta Therapeutics is advancing precision small molecule therapies for rare genetic diseases like hypophosphatasia (HPP) and Charcot-Marie-Tooth disease (CMT)
Nordic Science Investments VC Fund · 7 investments in the past 12 months
We partner with founders to transform unseen scientific discoveries into future breakthroughs, jointly moving businesses, people, and the world forward.
Show more
Investment focus
  • Apps, Food Processing, Food and Beverage
  • Seed
  • Finland
Portfolio highlights
  • AIATELLA — Automating medical image analysis
  • Solid IO — Solid IO is transforming precision oncology with organ-on-chip technology, delivering real-time, patient-specific insights to improve cancer treatment decisions.
  • SampleFacts — Next generation Dried Blood Spot sampling – separating cells and plasma at the point of collection.
Klimatet Invest VC Fund · Gothenburg, Vastra Gotaland, Sweden
Klimatet Invest is to create long-term value growth by investing relatively early in idea companies with good growth potential in cleantech and at the same time contributing to a more sustainable society.
Show more
Investment focus
  • Energy, Battery, GreenTech
  • Seed, Series A
  • Sweden
Portfolio highlights
  • Cellfion — Cellfion provides sustainable materials for next level clean energy storage and conversion devices.​
  • Ligna Energy — Ligna Energy is a green-tech start-up company developing disruptive technology and products for large-scale stationary electrical energy storage. The battery technology is made from cheap forest-based materials and organic polymers in combination with a water-based electrolyte. This is a unique solution foundation - enabling the world to shifttowards a fossil free energy system.
Bertebos Foundation VC Fund
Bertebos Foundation
Show more
Investment focus
  • Biotechnology, Manufacturing, Food Processing
  • Funding Round
  • Sweden
Portfolio highlights
  • Mycorena — Fungi-based, next-generation vegan protein. A food manufacturing solution superior to plants, using significantly less resources.
Additio Investment Group VC Fund · Barcelona, Catalonia, Spain
Value creation for Healthcare & Life Sciences Ventures through capital, expertise, international network.
Show more
Investment focus
  • Health Care, Biotechnology, Medical
  • Series A
  • United Kingdom, Sweden
Portfolio highlights
  • Orthox Ltd. — Founded to commercialise technology developed at Oxford University, Orthox aims to revolutionise the way cartilage injuries are treated. Trauma and erosion of the smooth, stiff cartilage in our joints leads to Osteoarthritis (OA) a debilitating disease, which affects over 300 million patients globally and costs the US economy alone over $128billion each year. Current therapies to repair damaged cartilage focus either on tissue regeneration or on functional replacement; Orthox’s exceptionally strong, resilient, regenerative hydrogel technology, FibroFix™ achieves both these goals, offering a unique solution for the millions of patients suffering from damage to their joints. Initially targeting the knee, Orthox has developed a compelling set of data on lead product FibroFix™ Cartilage which has secured major awards from multiple funding bodies and will shortly enter clinical trials. FibroFix™ technology will then be rolled out to treat other joints and Orthox also has pipeline developments beyond orthopaedics in which strength and tissue regeneration are key. Pipeline expansion is valuable as growth in the annual global biomaterials market will exceed $250 billion by 2025. Orthopaedic biomaterials will form the largest proportion of this and natural biomaterials, like FibroFix™, will be the fastest growing market segment. Orthox: Reducing Pain, Increasing Mobility, Regenerating Strength™.
  • Gedea Biotech — Gedea Biotech develops an antibiotic-free, safe and effective treatment of vaginal fungal infections. Vaginal yeast infections are a major problem that affects about 75% of all women at some point in life. Gedea Biotech's substance, GA101, is a natural substance that has always been part of their environment. It acts by lowering the pH as wellas providing a physical barrier protection and inhibiting biofilm formation. The first product will be a topical treatment of vaginal fungal infections.
  • Oxford Endovascular — Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel.This diverts the blood away from the aneurysm, allowing it to heal.
Fåhraeus Startup and Growth VC Fund · Lund, Skane Lan, Sweden
Fåhraeus Startup and Growth is a venture capital fund that invests early in life science and tech companies.
Show more
Investment focus
  • Medical, Health Care, Organic Food
  • Funding Round, Seed
  • Sweden
Portfolio highlights
  • Aplagon — Aplagon is committed to bringing unique, effective antithrombotic medicines with important safety advantages to patients with unmet needs.
  • Airsonett — Research-based medical technology company which leads the way in the development of non-pharmaceutical treatment for allergic asthma.
  • Nygen Analytics — Nygen empowers researchers to unlock insights from single-cell RNA-seq data with accessible, no-code solutions, facilitating reproducible transcriptomic research.
Hans and Barbara Bergström VC Fund
Hans and Barbara Bergström is a family investment office.
Show more
Investment focus
  • Biotechnology, Medical Device
  • Funding Round
  • Sweden
Portfolio highlights
Teknoinvest VC Fund · Oslo, Oslo, Norway
Teknoinvest is a premier Scandinavian venture capital company. They invest in areas of emerging technologies within the ITC and Life Sciences sectors. Their main geographical scope is Scandinavia and the USA. Teknoinvest was established as the first venture capital investment company. Teknoinvest is one of the most successful VC´s in Scandinaviaaccording to track record of value created for their investors.
Show more
Investment focus
  • Health Care, Biotechnology, Medical
  • Series B, Series A, Funding Round
  • Sweden, Norway, United States
Portfolio highlights
  • GLO — glō is a venture-backed company focused on the development and commercialization of advanced LED display products using nanotechnology. The unique nanotechnology is based on 11 years of research at Lund University’s Nanometer Structure Consortium. Headed by Professor Lars Samuelson, one of the world’s leading scientists in this field, who haspublished more than 500 papers related to this technology.glō's first office is in Lund, Sweden, where basic material research continues for the next generation nanotechnology. glō's research and product development along with pilot fabrication operation is carried out at glō-USA in Sunnyvale, California. In 2016, glō established an Asia office in Taipei, Taiwan, one of the largest and fastest-growing regions for LED lighting and display applications.glō's technology sidesteps the technical limitations of current planar LED technology. It allows for the creation of highly efficient, stable and ultimately unique red, green, blue (RGB) emitters out of one material system. It aims to achieve the industry’s best color stability and ultimately enables the growth of red, green and blue emitters on the same wafer. Highly-efficient white LEDs with high color rendering will be possible without the need for phosphor conversion. It is the next enabling technology for advanced display, illumination and automotive applications.glō nanowire light-emitting diodes (nLEDs) are based on its proprietary hetero-structured semiconductor nanowire epitaxial growth and process technologies for which standard manufacturing equipment and materials can be utilized.glō currently holds over 175 patents across US, Europe and Asia. These patents are not subject to any cross-licensing with the LED oligopoly. The glō team is constantly strengthening its intellectual property position in this technology and related applications.
  • SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The company’s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the company’s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
  • Sol Voltaics — Founded in 2007, Sol Voltaics AB is a venture-backed, development-stage nanotechnology company focused on development and commercialization of highly efficient, third-generation photovoltaic concentrator solar cells based on its proprietary heterostructured nanowire epitaxial growth and process technologies.
Plantbase Foundation VC Fund
Plantbase Foundation
Show more
Investment focus
  • Biotechnology, Manufacturing, Food Processing
  • Funding Round
  • Sweden
Portfolio highlights
  • Mycorena — Fungi-based, next-generation vegan protein. A food manufacturing solution superior to plants, using significantly less resources.
Investors by industry
Investors by country
VC (Venture Capital) Funds in Sweden by industry